リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Improved disk diffusion method for simple detection of group B streptococci with reduced penicillin susceptibility (PRGBS)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Improved disk diffusion method for simple detection of group B streptococci with reduced penicillin susceptibility (PRGBS)

Goto, Rikuko Jin, Wanchun Wachino, Jun-ichi Arakawa, Yoshichika Kimura, Kouji 名古屋大学

2023.03

概要

Highlights (85 characters, 3 to 5 bullet points)






PRGBS have a multidrug-resistance tendency and tend to be misclassified as PSGBS.
We improved the disk diffusion method for detecting PRGBS.
Using 73 PRGBS and 81 PSGBS, we determined more rational cutoff values.
Oxacillin, ceftizoxime, and ceftibuten disks showed high sensitivity and specificity.
This method can be performed without other special and/or expensive equipment.

1

1

Improved disk diffusion method for simple detection of group B streptococci with reduced

2

penicillin susceptibility (PRGBS)

3

4

Rikuko Gotoa, Wanchun Jina, 1, Jun-ichi Wachinoa, 2, Yoshichika Arakawaa, 2, Kouji Kimuraa*

5

aDepartment

6

Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

7

1Present

8

Moriyama-ku, Nagoya, Aichi 463-8521, Japan

9

2Present

10

of Bacteriology, Nagoya University Graduate School of Medicine, 65

address: College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori,

address: Laboratory of Microbiology, Department of Medical Technology, Faculty

of Medical Sciences, Shubun University, 6 Nikkou-cho, Ichinomiya, Aichi 491-0938, Japan.

11

12

13

Running title: Improved PRGBS detection method

14

Abstract: 50 words, Main text: 991 words.

15

*Address

16

Bacteriology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku,

17

Nagoya, Aichi 466-8550, Japan, TEL: +81-52-744-2106, FAX: +81-52-744-2107.

18

correspondence to Kouji Kimura, koujikim@med.nagoya-u.ac.jp, Department of

2

19

ABSTRACT (50 words)

20

We used 73 group B Streptococcus with reduced penicillin susceptibility (PRGBS)

21

isolates and determined more rational cutoff values of previously developed disk diffusion

22

method for detecting PRGBS using oxacillin, ceftizoxime, and ceftibuten disks. Using the

23

novel cutoff values, the three disks showed high sensitivity and specificity, which were above

24

90.0%.

25

26

KEYWORDS Streptococcus agalactiae, reduced penicillin susceptibility, detection method,

27

disk diffusion method, multidrug resistance

28
29

3

30

Streptococcus agalactiae (Group B Streptococcus, GBS) is the leading cause of neonatal

31

sepsis and bacterial meningitis, and is a causative pathogen of invasive diseases in the elderly

32

and those suffering from underlying medical conditions, such as diabetes [1–5]. β-Lactams

33

are the first-line agents for the intrapartum antibiotic prophylaxis and treatment of GBS

34

infections; all clinical isolates of GBS were previously considered to be uniformly

35

susceptible to β-lactams [5]. However, we reported clinical isolates of GBS with reduced

36

penicillin susceptibility (PRGBS) harboring amino acid substitutions, including V405A

37

and/or Q557E, in penicillin-binding protein (PBP) 2X [6, 7]. After our first report in 2008 (6),

38

clinical isolates of PRGBS that were confirmed to harbor amino acid substitutions in PBPs

39

were also reported from other groups in Japan [8], USA [9, 10], Canada [11, 12], Germany

40

[13], Mozambique [14], China [15], Hong Kong [16], and South Korea [17]. Besides reduced

41

penicillin susceptibility, PRGBS clinical isolates tend to be non-susceptible/resistant to

42

fluoroquinolones and macrolides, and exhibit multidrug-resistance tendency [18]. Therefore,

43

drug choice against infections caused by such multidrug-resistant PRGBS is narrower than

44

that caused by penicillin-susceptible GBS (PSGBS), although clinical outcomes of high dose

45

penicillins administration against PRGBS infections are unknown. Consequently, it is

46

necessary to detect such multidrug-resistant PRGBS accurately and rapidly to support better

4

47

drug choice against the infections.

48

The MICs of penicillin G for PRGBS (0.25-2 μg/ml) are near the “susceptible” breakpoints

49

(≤0.12 μg/ml) set by the Clinical and Laboratory Standards Institute (CLSI) [19], therefore,

50

misclassifications of PRGBS to PSGBS tend to happen [20]. To overcome this, we had

51

previously developed a simple disk diffusion method for detecting PRGBS using oxacillin,

52

ceftizoxime, and ceftibuten disks [21]. However, at that time, it was not long since we first

53

reported PRGBS, the number of PRGBS isolates used in that study was limited (16 strains of

54

PRGBS and 34 strains of PSGBS), and the cutoff values between PRGBS and PSGBS were

55

proposed tentatively. In this study, the number of PRGBS isolates we collected is larger than

56

the number of PRGBS isolates we possessed at that time. It was reported that the MICs of

57

three antibiotics, cefoxitin [22], cefaclor [23], and cefotiam [8], for GBS with reduced

58

β-lactam susceptibility (GBS-RBS) including PRGBS tended to be elevated; therefore, we

59

examined whether or not the three antibiotics disks: cefoxitin, cefaclor, and cefotiam, are

60

useful for detecting PRGBS in addition to oxacillin, ceftizoxime, and ceftibuten disks, and

61

tried to determine more rational cutoff values for each disk using a larger number of PRGBS

62

isolates.

63

We defined strains with the MICs of penicillin G ≥ 0.25 μg/ml as PRGBS and strains with

5

64

the MICs of penicillin G ≤ 0.12 μg/ml as PSGBS, as determined by the agar dilution method

65

that was set by the CLSI [19]. In accordance with this definition, we used 73 PRGBS and 81

66

PSGBS isolates. All 73 PRGBS isolates harbored amino acid substitutions in the PBPs.

67

Disk diffusion methods standardized by the CLSI were performed using 10U penicillin G, 1

68

μg oxacillin, 30 μg ceftizoxime, 30 μg ceftibuten, 30 μg cefoxitin, 30 μg cefaclor, and 30 μg

69

cefotiam disks (Eiken Chemical Co. Ltd., Tokyo, Japan). We compared the MICs of penicillin

70

G determined by the agar dilution method standardized by the CLSI and the diameters of the

71

growth inhibitory zones around each disk of the disk diffusion method. We performed

72

receiver operating characteristic (ROC) curve analysis and determined the cutoff value for

73

each

74

https://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html

75

2022]). We calculated the sensitivity and specificity for the determined cutoff values.

76

Comparison between the diameters of the growth inhibitory zones around each disk identified

77

from the disk diffusion method and the MICs of penicillin G determined by the agar dilution

78

method standardized by the CLSI are shown in Fig. 1. The selected cutoff values, sensitivity,

79

and specificity of each disk diffusion method are listed in Table 1 (also see Fig. S1 and S2).

80

The cutoff values of penicillin G, oxacillin, ceftizoxime, ceftibuten, cefoxitin, cefaclor, and

disk

using

the

statistical

analysis

software

Easy
[accessed

R

(EZR;

5

August

6

81

cefotiam, were 31 mm, 18 mm (previous tentative cutoff: 16 mm), 29 mm (previous tentative

82

cutoff: 28 mm), 19 mm (previous tentative cutoff: 19 mm), 24 mm, 29 mm, and 27 mm,

83

respectively. Among the seven disks investigated in this study, penicillin G, cefoxitin,

84

cefaclor, and cefotiam disks exhibited relatively lower sensitivity and specificity (82.2% and

85

86.4%, 78.1% and 87.7%, 64.4% and 87.7%, and 84.9% and 67.9%, respectively); therefore,

86

these disks are not very useful for detecting PRGBS using disk diffusion method. However,

87

oxacillin, ceftizoxime, and ceftibuten disks exhibited higher sensitivity and specificity

88

(93.2% and 98.8%, 90.4% and 95.1%, and 94.5% and 95.1%, respectively); consequently, the

89

disk diffusion method using these disks are very useful for detecting PRGBS. Moreover, in

90

the case of that we judge as PRGBS when the diameters around oxacillin or ceftibuten disks

91

are below or equal to cutoff values, the sensitivity and specificity were 97.3% and 95.1%,

92

respectively.

93

94

The fact that all clinical isolates used in this study are recovered from only Japan is one of
the limitations of this study.

95

Although most clinical isolates of PRGBS were recovered from respiratory specimens of

96

adults, especially the elderly, PRGBS clinical isolates from neonatal invasive GBS diseases

97

which were confirmed to harbor amino acid substitutions in PBP2X have been already

7

98

reported from Mozambique [14]. Therefore, active screening for PRGBS among clinical

99

isolates, including clinical isolates recovered from neonatal invasive GBS infections, using

100

this method for detecting PRGBS, is required to support the determination of better drug

101

choice against GBS infections and to facilitate the accumulation of clinical information as

102

well as promoting researches concerning PRGBS through efficient detection of PRGBS.

103

In conclusion, using the novel cutoff values, oxacillin, ceftizoxime, and ceftibuten disks

104

showed high sensitivity and specificity. This improvement to our previous disk diffusion

105

method for detecting PRGBS could serve as a promising method for detecting PRGBS at

106

bacterial laboratories in medical institutes worldwide, without need of other special and/or

107

expensive equipment.

108

8

109

Acknowledgments

110

We thank all members of Prof. Arakawa’s laboratory for their technical advice and beneficial

111

discussions. The manuscript was edited by Editage, an English language editing company.

112

This work was supported by the Research Program on Emerging/Re-emerging Infectious

113

Disease Project of the Japan Agency for Medical Research and Development, AMED. The

114

funding source had no involvement in study design, in the collection, in analysis and

115

interpretation of data, in the writing of the report, and in the decision to submit the journal for

116

publication.

117

Competing interests statement

118

The authors declare no competing interests.

9

119

References

120

[1] Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K, Sheridan

121

E. ...

この論文で使われている画像

参考文献

120

[1] Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K, Sheridan

121

E. Emerging trends in the epidemiology of invasive group B streptococcal disease in England

122

and Wales, 1991–2010. Clin Infect Dis 2013;57:682–688. http://doi.org/10.1093/cid/cit337.

123

[2] Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS,

124

Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER , Schuchat A,

125

Schrag SJ, Active Bacterial Core surveillance/Emerging Infections Program Network.

126

Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.

127

JAMA 2008;299:2056–2065. http://doi.org/10.1001/jama.299.17.2056.

128

[3] Okike IO, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebody B, Ladhani SN,

129

Anthony M, Ninis N, Heath PT, neoMen Study Group. Incidence, etiology, and outcome of

130

bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland:

131

prospective, enhanced, national population-based surveillance. Clin Infect Dis 2014;59:e150–

132

e157. http://doi.org/10.1093/cid/ciu514.

133

[4]

134

http://doi.org/10.1016/S0140-6736(98)07128-1.

135

[5] Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B

Schuchat

A.

Group

Streptococcus.

Lancet

1999;353:51–56.

10

136

Streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002;51:1–22.

137

[6] Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H,

138

Shibayama K, Arakawa Y. First molecular characterization of group B Streptococci with

139

reduced penicillin susceptibility. Antimicrob Agents Chemother 2008;52:2890–2897.

140

http://doi.org/10.1128/AAC.00185-08.

141

[7] Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y. Genetic

142

heterogeneity in pbp genes among clinically isolated group B streptococci with reduced

143

penicillin

144

http://doi.org/10.1128/AAC.00596-08.

145

[8] Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K,

146

Ubukata K, Invasive Streptococcal Disease Working Group. Capsular type and antibiotic

147

resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the

148

elderly, with invasive infections. Antimicrob Agents Chemother 2009;53:2650–2653.

149

http://doi.org/10.1128/AAC.01716-08.

150

[9] Dahesh S, Hensler ME, Van Sorge NM, Gertz Jr RE, Schrag S, Nizet V, Beall BW. Point

151

mutation in the group B Streptococcal pbp2x gene conferring decreased susceptibility to

152

β-lactam

susceptibility.

antibiotics.

Antimicrob

Antimicrob

Agents

Agents

Chemother

Chemother

2008;52:4258–4267.

2008;52:2915–2918.

11

153

http://doi.org/10.1128/AAC.00461-08.

154

[10] Metcalf BJ, Chochua

155

Rivers J, Mathis S, Jackson D, Glennen A, Lynfield R, McGee L, Beall B, Active Bacterial

156

Core surveillance team. Short-read whole genome sequencing for determination of

157

antimicrobial resistance mechanisms and capsular serotypes of current invasive

158

Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 2017;23:574.e7–

159

574.e14. http://doi.org/10.1016/j.cmi.2017.02.021.

160

[11] Gaudreau C, Lecours R, Ismaïl J, Gagnon S, Jetté L, Roger M. Prosthetic hip joint

161

infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and

162

ceftriaxone. J Antimicrob Chemother 2010;65:594–595. http://doi.org/10.1093/jac/dkp458.

163

[12] Longtin J, Vermeiren C, Shahinas D, Tamber GS, McGeer A, Low DE, Katz K, Pillai

164

DR. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin

165

susceptibility emerging after long-term oral suppressive therapy. Antimicrob Agents

166

Chemother 2011;55:2983–2985. http://doi.org/10.1128/AAC.01243-10.

167

[13] van der Linden M, Mamede R, Levina N, Helwing P, Vila-Cerqueira P, Carriço JA,

168

Melo-Cristino J, Ramirez M, Martins ER. Heterogeneity of penicillin-non-susceptible group

169

B streptococci isolated from a single patient in Germany. J Antimicrob Chemother

S, Gertz Jr RE, Hawkins PA, Ricaldi J, Li Z, Walker H, Tran T,

12

170

2020;75:296–299. http://doi.org/10.1093/jac/dkz465.

171

[14] Sigaúque B, Kobayashi M, Vubil D, Nhacolo A, Chaúque A, Moaine B, Massora S,

172

Mandomando I, Nhampossa T, Bassat Q, Pimenta F, Menéndez C, da Gloria Carvalho M,

173

Macete E, Schrag SJ. Invasive bacterial disease trends and characterization of group B

174

streptococcal isolates among young infants in southern Mozambique, 2001-2015. PLoS One

175

2018;13:e0191193. http://doi.org/10.1371/journal.pone.0191193.

176

[15] Hu Y, Kan Y, Zhang Z, Lu Z, Li Y, Leng C, Ji J, Song S, Shi H. New mutations of

177

penicillin-binding proteins in Streptococcus agalactiae isolates from cattle with decreased

178

susceptibility to penicillin. Microb Drug Resist 2018;24:1236–1241.

179

http://doi.org/10.1089/mdr.2017.0223.

180

[16]

181

Multidrug-resistant Streptococcus agalactiae strains

182

high penicillin and cefotaxime non-susceptibilities. Microorganisms 2020;8:1055.

183

http://doi.org/10.3390/microorganisms8071055.

184

[17] Yi A, Kim CK, Kimura K, Arakawa Y, Hur M, Yun YM, Moon HW. First case in Korea of

185

group B Streptococcus with reduced penicillin susceptibility harboring amino acid

186

substitutions in penicillin-binding protein 2X. Ann Lab Med 2019;39:414–416.

Li

C,

Sapugahawatte

DN,

Yang

Y,

Wong

found

KT,

in

Lo

human

NWS,

and

Ip

fish

M.

with

13

187

http://doi.org/10.3343/alm.2019.39.4.414.

188

[18] Kimura K, Nagano N, Nagano Y, Suzuki S, Wachino J, Shibayama Y, Arakawa Y. High

189

frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated

190

group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother

191

2013;68:539–542. http://doi.org/10.1093/jac/dks423.

192

[19] Clinical and Laboratory Standards Institute (CLSI). Performance standards for

193

antimicrobial susceptibility testing; 30th informational supplement. Wayne, PA: CLSI; 2020.

194

[20] Kimura K, Nagano N, Nagano Y, Wachino J, Shibayama K, Arakawa Y. Ability of the

195

VITEK® 2 system to detect group B streptococci with reduced penicillin susceptibility

196

(PRGBS). J Antimicrob Chemother 2013;68:1442–1444. http://doi.org/10.1093/jac/dkt008.

197

[21] Kimura K, Wachino J, Kurokawa H, Suzuki S, Yamane K, Shibata N, Arakawa Y.

198

Practical disk diffusion test for detecting group B Streptococcus with reduced penicillin

199

susceptibility. J Clin Microbiol 2009;47:4154–4157. http://doi.org/10.1128/JCM.02063-08.

200

[22] Fukigai S, Morimoto M, Kimura K, Doyama Y, Miyazaki A, Kamiya C, Banno H,

201

Morishima E, Onoda T, Nagano N, Jin W, Wachino J, Yamada K, Arakawa Y. Effectual

202

detection of group B streptococci with reduced penicillin susceptibility (PRGBS) by

203

commercially available methicillin-resistant-Staphylococcus aureus (MRSA)-selective agar.

14

204

Diagn Microbiol Infect Dis 2016;85:309–312.

205

http://doi.org/10.1016/j.diagmicrobio.2016.04.018.

206

[23] Nagano N, Nagano Y, Toyama M, Kimura K, Shibayama K, Arakawa Y.

207

Penicillin-susceptible group B streptococcal clinical isolates with reduced cephalosporin

208

susceptibility. J Clin Microbiol 2014;52:3406–3410. http://doi.org/10.1128/JCM.01291-14.

209

210

Author contributions statement

211

Rikuko Goto: Data curation, Formal analysis, Investigation, Validation, Writing – original

212

draft, Writing – review & editing

213

Wanchun Jin: Data curation, Formal analysis, Investigation, Validation, Writing – review &

214

editing

215

Jun-ichi Wachino: Data curation, Formal analysis, Investigation, Validation, Writing – review

216

& editing

217

Yoshichika Arakawa: Conceptualization, Funding acquisition, Supervision, Writing – review

218

& editing

219

Kouji Kimura: Conceptualization, Data curation, Formal analysis, Investigation, Validation,

220

Funding acquisition, Supervision, Writing – original draft, Writing – review & editing

15

221

222

16

223

Figure Legends

224

Fig. 1 Comparison between MICs of penicillin G determined by the agar dilution

225

methods and the diameters of growth inhibitory zones around each disk

226

The vertical axis is MICs of penicillin G determined by the agar dilution methods [μg/ml].

227

The horizontal axis is diameters [mm] of growth inhibitory zones around penicillin G disk

228

(A), oxacillin disk (B), ceftizoxime disk (C), ceftibuten disk (D), cefoxitin disk (E), cefaclor

229

disk (F), and cefotiam disk (G). Numbers in the intersection are the numbers of isolates. We

230

used 73 PRGBS (MICs of penicillin G ≥0.25 μg/ml) and 81 PSGBS (MICs of penicillin G

231

≤0.12 μg/ml). Penicillin G MICs ≤0.12 μg/ml is the “susceptible” breakpoint set by the CLSI.

232

The horizontal line shows this breakpoint. The vertical line shows the cutoff values

233

determined by the receiver operating characteristic (ROC) curve analysis.

234

235

Fig. S1 Receiver operating characteristic (ROC) curve analysis

236

ROC curve concerning comparison between MICs of penicillin G determined by the agar

237

dilution methods and the diameters of growth inhibitory zones around each disk in Figure 1.

238

Each block among (A)-(D) is the disk diffusion method using penicillin G disk (A), oxacillin

239

disk (B), ceftizoxime disk (C), and ceftibuten disk (D). The vertical axis is the sensitivity and

17

240

the horizontal axis is the specificity. The three numbers in each blocks show cutoff values

241

(specificity, sensitivity).

242

Fig. S2 Receiver operating characteristic (ROC) curve analysis

243

ROC curve concerning comparison between MICs of penicillin G determined by the agar

244

dilution method and the diameters of growth inhibitory zones around each disk in Figure 1.

245

Each block among (A)-(C) is the disk diffusion method using cefoxitin disk (A), cefaclor disk

246

(B), and cefotiam disk (C). The vertical axis is the sensitivity and the horizontal axis is the

247

specificity. The three numbers in each blocks show the cutoff value (specificity, sensitivity).

248

18

249

Table 1. Cutoff values, sensitivity, and specificity of the seven disks identified from the

250

disk diffusion method

251

Disk

Cutoff [Previous Sensitivity (%)

Specificity

tentative cutoff]

(%)

(mm)

Penicillin G

31

82.2

86.4

Oxacillin

18 [16]

93.2

98.8

Ceftizoxime

29 [28]

90.4

95.1

Ceftibuten

19 [19]

94.5

95.1

Cefoxitin

24

78.1

87.7

Cefaclor

29

64.4

87.7

Cefotiam

27

84.9

67.9

97.3

95.1

Combination

Ceftibuten)

252

253

(Oxacillin

or

PCG MIC [μg/ml]

PCG MIC [μg/ml]

Zone of Inhibition Ceftizoxime disks [mm]

Zone of Inhibition Ceftibuten disks [mm]

PCG MIC [μg/ml]

Zone of Inhibition Cefoxitin disks [mm]

Zone of Inhibition Cefaclor disks [mm]

PCG MIC [μg/ml]

Zone of Inhibition Oxacillin disks [mm]

PCG MIC [μg/ml]

PCG MIC [μg/ml]

PCG MIC [μg/ml]

Zone of Inhibition Penicillin G disks [mm]

Zone of Inhibition Cefotiam disks [mm]

Figure 1

Penicillin G disks

Oxacillin disks

Ceftizoxime disks

Ceftibuten disks

Figure S1

Cefoxitin disks

Cefotiam disks

Cefaclor disks

Figure S2

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る